Shalby Limited (NSE:SHALBY) filed an exchange disclosure on 18 August 2026 under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015, informing stock exchanges that Mr. Deepak Anand has resigned as Chief Executive Officer of Shalby Medtech Limited, a wholly-owned subsidiary, with his last working day confirmed as 4 September 2026.
Key Highlights
- Mr. Deepak Anand resigned as CEO of Shalby Medtech Limited, a wholly-owned subsidiary of Shalby Limited, effective close of business on 4 September 2026.
- The resignation was submitted by letter dated 18 August 2026, citing a personal decision to relocate abroad as the sole stated reason.
- Shalby Limited confirmed in its exchange filing that no other material reason beyond those stated in the resignation letter exists for the departure.
- The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of SEBI's Listing Regulations, 2015.
About the Company
Shalby Limited (NSE:SHALBY), headquartered in Ahmedabad, Gujarat, is a multi-specialty hospital chain primarily focused on orthopaedic and joint replacement procedures. The company operates hospitals across multiple Indian cities including Ahmedabad, Surat, Jaipur, and Indore. Shalby Medtech Limited is a wholly-owned subsidiary engaged in the medical technology segment within the broader Shalby Group.
Announcement in Detail
According to the filing submitted to the National Stock Exchange and BSE on 18 August 2026, Mr. Deepak Anand, who held the position of Chief Executive Officer at Shalby Medtech Limited, tendered his resignation via a letter dated the same day. His last working day with the organisation is stated as 4 September 2026, which also marks the effective date of his cessation from the role.
In his resignation letter, addressed to the Managing Director of Shalby Medtech Limited, Mr. Anand stated clearly that his decision was driven entirely by a personal choice to move abroad, and he explicitly confirmed that there is no other reason, material or otherwise, for his departure. He also expressed his commitment to ensuring a smooth handover of responsibilities during the remaining period. The Company Secretary of Shalby Limited, Mr. Tushar Shah, countersigned and submitted the disclosure on behalf of the listed entity, affirming the same position regarding the absence of any additional material reason.
Impact on Investors
Investors will note that this change affects the senior management layer of Shalby Medtech Limited, a wholly-owned subsidiary, rather than the board or executive leadership of the listed parent entity, Shalby Limited. The filing shows no successor has been named as of the disclosure date, meaning the medtech subsidiary will undergo a leadership transition whose timeline and terms have not been publicly communicated through this announcement.
Shareholders will observe that the company has confirmed no material undisclosed reason underlies the resignation, which limits the informational scope of the disclosure to the stated personal grounds. The filing does not indicate any operational disruption, change in subsidiary strategy, or financial impact attributable to this management change.
Sector / Market Context
India's medical technology sector has attracted increased regulatory and commercial attention in recent years, with the Ministry of Health and Family Welfare introducing a national medtech policy framework to support domestic manufacturing and innovation. Within this backdrop, leadership continuity at medtech subsidiaries of listed hospital groups carries operational significance, particularly as companies expand their device and technology portfolios alongside core clinical services. The broader hospital sector, of which Shalby is a part, has seen consistent capacity expansion across tier-two Indian cities in recent annual periods.